CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE)–Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2023.
“2023 was a year of substantial progress for Repare. We advanced each of the four programs in our portfolio and set the stage for meaningful data readouts and new clinical trial starts this year,” said Lloyd M. Segal, President and Chief Executive Officer of Repare. “In particular and as leaders and innovators in PKMYT1 inhibition, we look forward to data readouts across all ongoing lunresertib clinical trials in 2024 and are excited to begin a lunresertib and WEE1 combination clinical trial in partnership with Debiopharm.”
2023 and Recent Portfolio Highlights:
-
Lunresertib
- Presented initial positive data from its ongoing Phase 1 MYTHIC trial evaluating lunresertib (RP-6306) alone and in combination with camonsertib in patients with advanced solid tumors harboring CCNE1 amplification or FBXW7 or PPP2R1A deleterious alterations at the 2023 American Association for Cancer Research (AACR)-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Initial combination data included an overall RECIST response rate of 50% in ten patients with heavily pre-treated gynecological tumors at the preliminary recommended Phase 2 dose.
- Announced a partnership with Debiopharm to explore the potential clinical synergy of Debio 0123, a highly selective clinical WEE1 inhibitor, and lunresertib, with dosing of the first patient expected to occur in the first half of 2024 and for which the companies have developed substantial pre-clinical validation. Repare will sponsor the global clinical trial as a new arm in the ongoing MYTHIC trial, with costs being shared equally by Debiopharm and Repare.
-
Camonsertib
- Presented initial clinical data from the Phase 1/2 TRESR and ATTACC trials evaluating camonsertib (RP-3500) in combination with three poly (ADP-ribose) polymerase (PARP) inhibitors in a Clinical Trials Plenary Session at the 2023 AACR Annual Meeting. Camonsertib, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase), showed 48% overall clinical benefit rate in patients with advanced solid tumors across tumor types regardless of choice of PARP inhibitor or platinum resistance, with a favorable safety and tolerability profile. Data from the TRESR trial were also published in Nature Medicine highlighting the clinical benefit of camonsertib in advanced solid tumors.
- Upon dosing of the first patient with camonsertib in Roche’s Phase 2 TAPISTRY trial (NCT04589845), Repare earned a $40 million milestone payment from its collaboration with Roche, which was subsequently received in February 2024. In October 2023, Roche also dosed the first patient in a camonsertib-based arm in its Phase 1b/2 clinical trial of multiple immunotherapy-based treatment combinations in participants with metastatic non-small cell lung cancer (Morpheus Lung; NCT03337698).
- Since inception of the Roche camonsertib collaboration, Repare has earned a cumulative total of $182.6 million pursuant to the Roche collaboration agreement, including the upfront payment, the milestone payment, as well as additional reimbursements from Roche. In February 2024, Repare received written notice from Roche of their election to terminate the Roche collaboration agreement. The termination will become effective in May 2024, at which time Repare will regain global development and commercialization rights for camonsertib from Roche.
-
RP-1664
- Dosed the first patient in the multicenter, open-label Phase 1 dose escalation trial of RP-1664 in adult and adolescent patients with TRIM37-high solid tumors in February 2024. Repare disclosed polo-like kinase 4 (PLK4) as the target of the RP-1664 development program and reported that RP-1664 demonstrated potent and selective inhibition of PLK4 and synthetic lethality in TRIM37-high tumor cells in preclinical studies.
-
RP-3467
- Reported comprehensive preclinical data for RP-3467, a potential best-in-class Polθ ATPase inhibitor. RP-3467 demonstrated complete, sustained regressions preclinically in combination with PARP inhibitors, and compelling anti-tumor activity in combination with radioligand therapy and chemotherapy.
2024 Outlook:
- Initiate a Phase 1/1b clinical trial of lunresertib and Debio 0123, a WEE1 inhibitor, in the first half of 2024 as a fourth arm of the ongoing MYTHIC clinical trial.
- Report initial data from the Phase 1 MINOTAUR trial evaluating lunresertib in combination with FOLFIRI for the treatment of advanced solid tumors in the first half of 2024.
- Disclose additional camonsertib clinical development plans beyond the TRESR and ATTACC clinical trials sponsored by Repare in the second quarter of 2024.
- Report data from the dose expansion cohorts of the Phase 1 MYTHIC trial evaluating lunresertib in combination with camonsertib in selectively advanced solid tumors in the second half of 2024.
- Report initial data from the Phase 1 MAGNETIC trial evaluating lunresertib in combination with gemcitabine for the treatment of advanced solid tumors in the second half of 2024. Enrollment in this trial is now closed.
- Initiation of a Phase 1 dose finding trial of RP-3467 in the second half of 2024.
Fourth Quarter and Full Year 2023 Financial Results:
- Cash, cash equivalents, and marketable securities: Cash, cash equivalents, and marketable securities as of December 31, 2023 were $223.6 million. In February 2024, Repare received a $40 million milestone payment from Roche upon dosing of the first patient with camonsertib in Roche’s TAPISTRY trial. The Company believes that its cash, cash equivalents, and marketable securities are sufficient to fund its operations into mid-2026.
- Revenue from collaboration agreements: Revenue from collaboration agreements was $13.0 million and $51.1 million for the three- and twelve-month periods ended December 31, 2023, respectively, as compared to $18.2 million and $131.8 million for the three- and twelve-month periods ended December 31, 2022, respectively. The decrease in revenue for the three-month period was due to lower deferred revenue recognized from the Roche collaboration and the BMS collaboration. The decrease in revenue for the twelve-month period was primarily due to a decrease in revenue recognized under the Roche collaboration mainly as a result of the $108.0 million revenue recognized in 2022 pursuant to the satisfaction of the Company’s performance obligations for the issuance of the combined licenses and the clinical trial materials transferred. The decrease in the twelve-month period was partially offset by higher deferred revenue recognized from the BMS collaboration and the Ono collaboration.
- Research and development expenses, net of tax credits (Net R&D): Net R&D expenses were $35.3 million and $133.6 million for the three- and twelve-month periods ended December 31, 2023, respectively, as compared to $29.9 million and $119.1 million for the three- and twelve-month periods ended December 31, 2022, respectively. The increase in Net R&D expenses for the three- and twelve-month periods were primarily due to higher personnel-related costs and direct external costs related to the progress of our lunresertib clinical program, as well as the advancement of preclinical programs into IND-enabling studies.
- General and administrative (G&A) expenses: G&A expenses were $8.6 million and $33.8 million for the three- and twelve-month periods ended December 31, 2023, respectively, compared to $7.9 million and $32.6 million for the three- and twelve-month periods ended December 31, 2022, respectively. The increase in G&A expenses was primarily due to higher personnel-related costs, partially offset by lower D&O insurance premiums and reduced professional fees associated with the Roche collaboration agreement.
- Net loss: Net loss was $28.0 million, or $0.67 per share, and $93.8 million, or $2.23 per share, in the three- and twelve-month periods ended December 31, 2023, respectively, and $31.7 million, or $0.75 per share, and $29.0 million, or $0.69 per share, in the three- and twelve-month periods ended December 31, 2022, respectively.
About Repare Therapeutics’ SNIPRx® Platform
Repare’s SNIPRx® platform is a genome-wide CRISPR-based screening approach that utilizes proprietary isogenic cell lines to identify novel and known synthetic lethal gene pairs and the corresponding patients who are most likely to benefit from the Company’s therapies based on the genetic profile of their tumors. Repare’s platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx® screening, in order to selectively target those tumors in patients most likely to achieve clinical benefit from resulting product candidates.
About Repare Therapeutics Inc.
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1/2 clinical development; camonsertib (also known as RP-3500), a potential leading ATR inhibitor currently in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical Polθ ATPase inhibitor program; as well as additional, undisclosed preclinical programs. For more information, please visit www.reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.
SNIPRx® is a registered trademark of Repare Therapeutics Inc.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in Canada. All statements in this press release other than statements of historical facts are “forward-looking statements. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the design, objectives, initiation, timing, progress and results of current and future preclinical studies and clinical trials of the Company’s product candidates, including its Phase 1 MYTHIC trial evaluating lunresertib alone and in combination with camonsertib, its MINOTAUR trial evaluating lunresertib in combination with FOLFIRI, its MAGNETIC trial evaluating lunresertib in combination with gemcitabine, its Phase 1/1b trial of Debio 0123 and lunresertib in partnership with Debiopharm, its Phase 1 trial of RP-1664, its Phase 1 trial of RP-3467, and its additional clinical development plans for camonsertib beyond the TRESR and ATTACC clinical trials; the tolerability, efficacy and clinical progress of camonsertib, lunresertib, RP-1664 and RP-3467; the potential of RP-3467 as a best-in-class Polθ ATPase inhibitor; the potential synergy of Debio 0123 and lunresertib and potential benefits of the collaboration; the Company’s anticipated cash runway; and the benefits and ability to discover further targets and clinical candidates from the Company’s discovery platform. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including the conflict in Ukraine and the conflict in the Middle East, heightened inflation and uncertain credit and financial markets, on the Company’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company’s ability to realize the benefits of its collaboration and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (“SEC”) and the Québec Autorité des Marchés Financiers (“AMF”) on February 28, 2024. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit reparerx.com and follow Repare on Twitter at @RepareRx and on LinkedIn at https://www.linkedin.com/company/repare-therapeutics/.
|
Repare Therapeutics Inc. |
||||||||
|
Consolidated Balance Sheets |
||||||||
|
(Unaudited) |
||||||||
|
(Amounts in thousands of U.S. dollars, except share data) |
||||||||
|
|
|
As of December 31, |
|
|||||
|
|
|
2023 |
|
|
2022 |
|
||
|
ASSETS |
|
|
|
|
|
|
||
|
Current assets: |
|
|
|
|
|
|
||
|
Cash and cash equivalents |
|
$ |
111,268 |
|
|
$ |
159,521 |
|
|
Marketable securities |
|
|
112,359 |
|
|
|
184,420 |
|
|
Income tax receivable |
|
|
10,813 |
|
|
|
— |
|
|
Other current receivables |
|
|
4,499 |
|
|
|
4,323 |
|
|
Prepaid expenses |
|
|
4,749 |
|
|
|
5,715 |
|
|
Total current assets |
|
|
243,688 |
|
|
|
353,979 |
|
|
Property and equipment, net |
|
|
4,215 |
|
|
|
4,228 |
|
|
Operating lease right-of-use assets |
|
|
3,326 |
|
|
|
5,371 |
|
|
Income tax receivable |
|
|
2,276 |
|
|
|
— |
|
|
Other assets |
|
|
396 |
|
|
|
497 |
|
|
TOTAL ASSETS |
|
$ |
253,901 |
|
|
$ |
364,075 |
|
|
LIABILITIES AND SHAREHOLDERS’ EQUITY |
|
|
|
|
|
|
||
|
Current liabilities: |
|
|
|
|
|
|
||
|
Accounts payable |
|
$ |
2,400 |
|
|
$ |
461 |
|
|
Accrued expenses and other current liabilities |
|
|
24,057 |
|
|
|
21,645 |
|
|
Operating lease liabilities, current portion |
|
|
2,400 |
|
|
|
2,171 |
|
|
Deferred revenue, current portion |
|
|
10,222 |
|
|
|
53,102 |
|
|
Income tax payable |
|
|
— |
|
|
|
1,240 |
|
|
Total current liabilities |
|
|
39,079 |
|
|
|
78,619 |
|
|
Operating lease liabilities, net of current portion |
|
|
1,010 |
|
|
|
3,257 |
|
|
Deferred revenue, net of current portion |
|
|
1,730 |
|
|
|
2,682 |
|
|
TOTAL LIABILITIES |
|
|
41,819 |
|
|
|
84,558 |
|
|
Commitments and Contingencies |
|
|
|
|
|
|
||
|
SHAREHOLDERS’ EQUITY: |
|
|
|
|
|
|
||
|
Preferred shares, no par value per share; unlimited shares authorized as of December 31, 2023 and December 31, 2022, respectively; 0 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively |
|
|
— |
|
|
|
— |
|
|
Common shares, no par value per share; unlimited shares authorized as of December 31, 2023 and December 31, 2022; 42,176,041 and 42,036,193 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively |
|
|
483,350 |
|
|
|
482,032 |
|
|
Additional paid-in capital |
|
|
61,813 |
|
|
|
37,226 |
|
|
Accumulated other comprehensive loss |
|
|
28 |
|
|
|
(428 |
) |
|
Accumulated deficit |
|
|
(333,109 |
) |
|
|
(239,313 |
) |
|
TOTAL SHAREHOLDERS’ EQUITY |
|
|
212,082 |
|
|
|
279,517 |
|
|
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY |
|
$ |
253,901 |
|
|
$ |
364,075 |
|
|
Repare Therapeutics Inc. |
||||||||
|
Consolidated Statements of Operations |
||||||||
|
(Unaudited) |
||||||||
|
(Amounts in thousands of U.S. dollars, except share and per share data) |
||||||||
|
|
|
Year Ended |
|
|||||
|
|
|
2023 |
|
|
2022 |
|
||
|
Revenue: |
|
|
|
|
|
|
||
|
Collaboration agreements |
|
$ |
51,133 |
|
|
$ |
131,830 |
|
|
Operating expenses: |
|
|
|
|
|
|
||
|
Research and development, net of tax credits |
|
|
133,593 |
|
|
|
119,066 |
|
|
General and administrative |
|
|
33,764 |
|
|
|
32,560 |
|
|
Total operating expenses |
|
|
167,357 |
|
|
|
151,626 |
|
|
Loss from operations |
|
|
(116,224 |
) |
|
|
(19,796 |
) |
|
Other income (expense), net |
|
|
|
|
|
|
||
|
Realized and unrealized (loss) gain on foreign exchange |
|
|
(170 |
) |
|
|
308 |
|
|
Interest income |
|
|
13,334 |
|
|
|
5,631 |
|
|
Other expense, net |
|
|
(119 |
) |
|
|
(43 |
) |
|
Total other income, net |
|
|
13,045 |
|
|
|
5,896 |
|
|
Loss before income taxes |
|
|
(103,179 |
) |
|
|
(13,900 |
) |
|
Income tax benefit (expense) |
|
|
9,383 |
|
|
|
(15,147 |
) |
|
Net loss |
|
$ |
(93,796 |
) |
|
$ |
(29,047 |
) |
|
Other comprehensive loss: |
|
|
|
|
|
|
||
|
Unrealized gain (loss) on available-for-sale marketable securities |
|
|
456 |
|
|
|
(428 |
) |
|
Total other comprehensive income (loss) |
|
$ |
456 |
|
|
$ |
(428 |
) |
|
Comprehensive loss |
|
$ |
(93,340 |
) |
|
$ |
(29,475 |
) |
|
Net loss per share attributable to common shareholders—basic and diluted |
|
$ |
(2.23 |
) |
|
$ |
(0.69 |
) |
|
Weighted-average common shares outstanding—basic and diluted |
|
|
42,093,293 |
|
|
|
41,922,042 |
|
|
|
|
Three Months Ended |
|
|||||
|
|
|
2023 |
|
|
2022 |
|
||
|
Key financial highlights: |
|
|
|
|
|
|
||
|
Revenues from collaboration agreements |
|
$ |
13,047 |
|
|
$ |
18,198 |
|
|
Research and development, net of tax credits |
|
$ |
35,266 |
|
|
$ |
29,891 |
|
|
General and administrative |
|
$ |
8,648 |
|
|
$ |
7,939 |
|
|
Net loss |
|
$ |
(28,030 |
) |
|
$ |
(31,658 |
) |
|
Net loss per share attributable to common shareholders—basic and diluted |
|
$ |
(0.67 |
) |
|
$ |
(0.75 |
) |
|
Weighted-average common shares outstanding—basic and diluted |
|
|
42,139,096 |
|
|
|
41,979,869 |
|
Contacts
Repare:
Robin Garner
Vice President and Head of Investor Relations
Repare Therapeutics Inc.
investor@reparerx.com
Investors:
Matthew DeYoung
Argot Partners
repare@argotpartners.com
Media:
David Rosen
Argot Partners
david.rosen@argotpartners.com
212-600-1902